Mereo BioPharma GroupMREO +3.62%19 Pretax Margin % is % as of Mar. 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Mereo BioPharma Group ranks worse than 91.5% on this metric.
The historical rank and industry rank for Mereo BioPharma Group's Pretax Margin % or its related term are showing as below:
MREO'
s Pretax Margin % Range Over the Past 10 Years
Min: -8375.6 Med: -299.98 Max: 39.05
Current: -7142
MREO's Pretax Margin % is ranked worse than 91.5% of 941
companies
in the Biotechnology industry
Industry Median: -90.37
vs MREO: -7142.00
Mereo BioPharma Group (NAS:MREO) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Mereo BioPharma Group Pretax Margin % Related Terms
Mereo BioPharma Group Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Mereo BioPharma Group's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MREO vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Mereo BioPharma Group's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mereo BioPharma Group Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Mereo BioPharma Group's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mereo BioPharma Group (MREO) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mereo BioPharma Group and its competitors. According to the industry distribution chart, Mereo BioPharma Group ranks #861 out of 941 companies in the Biotechnology industry, placing it in the top 91.5%.
Is Mereo BioPharma Group's Pretax Margin % too high?
Mereo BioPharma Group's current Pretax Margin % is %. Based on the distribution chart, Mereo BioPharma Group ranks #861 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #861 out of 941 companies for Pretax Margin %. This places Mereo BioPharma Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current Pretax Margin % of %. The current Pretax Margin % is %. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score
Get the complete analysis for MREO
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MREO has been successfully added to your 
